Low Dose Cyclophosphamide for Ovarian Cancer Treatment
Author Information
Author(s): Samaritani Riccardo, Corrado Giacomo, Vizza Enrico, Sbiroli Carlo
Primary Institution: Division of Medical Oncology, San Carlo IDI Sanità Hospital, Rome, Italy
Hypothesis
Can metronomic chemotherapy with low-dose cyclophosphamide be an effective palliative treatment for advanced ovarian cancer?
Conclusion
Low-dose oral cyclophosphamide showed significant efficacy in stabilizing disease in a patient with advanced ovarian cancer.
Supporting Evidence
- The patient had a progression-free survival time of 65 months on low-dose cyclophosphamide.
- The patient experienced no side effects during the treatment.
- The treatment allowed the patient to maintain a normal working and social life.
Takeaway
This study shows that giving a small amount of chemotherapy every day can help some patients with ovarian cancer feel better and live longer.
Methodology
The patient received daily low-dose oral cyclophosphamide as palliative chemotherapy after failing standard treatments.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 36-year-old nulliparous woman with advanced stage IIIC ovarian cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website